![[Next-Generation Sequencing Book]](https://www.bioinformatics.org/images/ack_banners/NGS-Book-1-728x90.png)
-
Tumor mutation burden (TMB) is a prediction of the number of mutations carried by tumor cells and has been paid more and more attention in biomarker research. By measuring TMB, the cancer cell now has a unique fingerprint of natural and mutated proteins. Based on our cutting-edge SuPrecision™ platform, Creative Biolabs has accumulated extensive experience in performing whole exome sequencing (WES) and comprehensive analysis. Our scientists have developed a novel algorithmic approach for TMB analysis for response to checkpoint inhibitor immunotherapy. By comparing DNA sequences from a patient's healthy tissues and tumor cells, our scientists can determine the number of acquired somatic mutations present in tumors but not in normal tissues. We are confident in providing clients with the best service at the most competitive cost.
https://www.creative-biolabs.com/suprecision/tumor-mutational-burden-tmb-analysis-for-response-to-checkpoint-immunotherapy.htm
![[Photo]](https://www.bioinformatics.org/images/photo.php?photo_id=23460)
Discussion forums: Resources: Tumor Mutational Burden (TMB) analysis for response to checkpoint immunotherapy
Expanded view | Monitor forum | Save place
Start a new thread:
You have to be logged in to post a reply.